Follicular Lymphoma Treatment Market is expected to reach US$ XX Bn by 2026 from US$ XX Bn in 2017 at a CAGR of XX% Lymphoma is cancer of lymphatic system, which disturbs the cells of the immune system known as lymphocytes causes’ growth of the cells. Lymphocytes are the white blood cells which protects the body from the infection. It is of two types one is Non-Hodgkin and another is Hodgkin lymphoma. Follicular lymphoma is a type of Non-Hodgkin Lymphoma which affects the lymphocytes. Follicular lymphoma have symptoms like increase of the lymph nodes in the neck, shortness of breath, weight loss, night sweats. Rising prevalence of follicular lymphoma, family history of the disease, and increasing incidence of blood disorders worldwide are proving to be the key driving factors for Follicular Lymphoma Treatment Market. In addition, increasing research and development activities for innovation of newer drugs and treatment methods and technological advancements in disease diagnosis would further fuel the follicular lymphoma market in the near future. However, the probable restraints like strict regulatory requirements for drug approval, high treatment cost, and adverse effects associated with different treatment methods should also be taken into account. Follicular Lymphoma Treatment Market is segmented by Treatment Type, End User, and Geography. The key factors which drive the global follicular lymphoma treatment market in the forecast period are increasing occurrence of follicular lymphoma, Genetic disease, and growing rate of blood disorders at a global level. However, firm regulatory requirements for drug approval, huge treatment cost, and adverse results related with different treatment methods may restrain the market. Furthermore new therapies like monoclonal antibodies with government initiatives for cancer management are expected to boost the market.
Radiation and chemotherapy are currently reactive treatment for follicular lymphoma. However, radiation alone is used for the treatment of follicular lymphoma in maximum cases. In complex cases chemotherapy alone is used for the treatment of follicular lymphoma. Moreover, Targeted Therapy is better than chemotherapy and Radiation, as they act directly by targeting on tumour cells.
Geographically North America follicular lymphoma treatment market is is expected to hold maximum market share during forecast period huge growth in the occurrence of the disease in the region, mainly in the U.S. The market in Europe is also expected to expand significantly during the estimate period, because of firm health care infrastructure and rise in the occurrence of follicular lymphoma in the region.
Some of the important players working at a global level contain Roche, Spectrum Pharmaceuticals, Johnson and Johnson, CTI Biopharma, Celgene, AbbVie Inc., Novartis, Amgen, Merck & Co. (MRK), Seattle Genetics, Pharmacyclics/ Bristol-Myers Squibb (BMY), and Bayer AG’S. In 2017, Bayer AG’s has launched advanced drug, Aliqopa, also known as copanlisib, which is a kinase inhibitor which block certain enzymes responsible in cell growth.